Cargando…

Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by increased levels of desmoplasia that contributes to reduced drug delivery and poor treatment outcomes. In PDAC, the stromal content can account for up to 90% of the total tumor volume. The complex interplay between str...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Mohammad A., Zhung, Wonho, Stanley, Margaret Elizabeth, Formica, Sydney, Grimaldo-Garcia, Stacey, Obaid, Girgis, Hasan, Tayyaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443673/
https://www.ncbi.nlm.nih.gov/pubmed/35583476
http://dx.doi.org/10.1021/acs.molpharmaceut.2c00260
_version_ 1785093885187325952
author Saad, Mohammad A.
Zhung, Wonho
Stanley, Margaret Elizabeth
Formica, Sydney
Grimaldo-Garcia, Stacey
Obaid, Girgis
Hasan, Tayyaba
author_facet Saad, Mohammad A.
Zhung, Wonho
Stanley, Margaret Elizabeth
Formica, Sydney
Grimaldo-Garcia, Stacey
Obaid, Girgis
Hasan, Tayyaba
author_sort Saad, Mohammad A.
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by increased levels of desmoplasia that contributes to reduced drug delivery and poor treatment outcomes. In PDAC, the stromal content can account for up to 90% of the total tumor volume. The complex interplay between stromal components, including pancreatic cancer associated fibroblasts (PCAFs), and PDAC cells in the tumor microenvironment (TME) have a significant impact on prognoses and thus needs to be recapitulated in vitro when evaluating various treatment strategies. This study is a systematic evaluation of photodynamic therapy (PDT) in 3D heterotypic coculture models of PDAC with varying ratios of patient derived PCAFs that simulate heterogenous PDAC tumors with increasing stromal content. The efficacy of antibody-targeted PDT (photoimmunotherapy; PIT) using cetuximab photoimmunoconjugates (PICs) of benzoporphyrin derivative (BPD) is contrasted with that of liposomal BPD (Visudyne(®)), which is currently in PDT clinical trials for PDAC. We demonstrate that both Visudyne(®)-PDT and PIT were effective in heterotypic PDAC 3D spheroids with a low stromal content. However, as the stromal content increases above 50% in the 3D spheroids, the efficacy of Visudyne(®)-PDT is reduced by up to 10-fold, while PIT retains its efficacy. PIT was found to be 10-fold, 19-fold and 14-fold more phototoxic in spheroids with 50%, 75% and 90% PCAFs, respectively, as compared to Visudyne(®)-PDT. This marked difference in efficacy is attributed to the ability of PICs to penetrate and distribute within spheroids with a higher stromal content, whereas Visudyne(®) is restricted to the spheroid periphery. This study thus demonstrates how the stromal content in PDAC spheroids directly impacts their responsiveness to PDT and proposes PIT to be a highly suited treatment option for desmoplastic tumors with particularly high degrees of stromal content.
format Online
Article
Text
id pubmed-10443673
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-104436732023-08-22 Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids Saad, Mohammad A. Zhung, Wonho Stanley, Margaret Elizabeth Formica, Sydney Grimaldo-Garcia, Stacey Obaid, Girgis Hasan, Tayyaba Mol Pharm Article Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by increased levels of desmoplasia that contributes to reduced drug delivery and poor treatment outcomes. In PDAC, the stromal content can account for up to 90% of the total tumor volume. The complex interplay between stromal components, including pancreatic cancer associated fibroblasts (PCAFs), and PDAC cells in the tumor microenvironment (TME) have a significant impact on prognoses and thus needs to be recapitulated in vitro when evaluating various treatment strategies. This study is a systematic evaluation of photodynamic therapy (PDT) in 3D heterotypic coculture models of PDAC with varying ratios of patient derived PCAFs that simulate heterogenous PDAC tumors with increasing stromal content. The efficacy of antibody-targeted PDT (photoimmunotherapy; PIT) using cetuximab photoimmunoconjugates (PICs) of benzoporphyrin derivative (BPD) is contrasted with that of liposomal BPD (Visudyne(®)), which is currently in PDT clinical trials for PDAC. We demonstrate that both Visudyne(®)-PDT and PIT were effective in heterotypic PDAC 3D spheroids with a low stromal content. However, as the stromal content increases above 50% in the 3D spheroids, the efficacy of Visudyne(®)-PDT is reduced by up to 10-fold, while PIT retains its efficacy. PIT was found to be 10-fold, 19-fold and 14-fold more phototoxic in spheroids with 50%, 75% and 90% PCAFs, respectively, as compared to Visudyne(®)-PDT. This marked difference in efficacy is attributed to the ability of PICs to penetrate and distribute within spheroids with a higher stromal content, whereas Visudyne(®) is restricted to the spheroid periphery. This study thus demonstrates how the stromal content in PDAC spheroids directly impacts their responsiveness to PDT and proposes PIT to be a highly suited treatment option for desmoplastic tumors with particularly high degrees of stromal content. 2022-07-04 2022-05-18 /pmc/articles/PMC10443673/ /pubmed/35583476 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00260 Text en https://creativecommons.org/licenses/by-nc/4.0/It is made available under aCC-BY-NC 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Article
Saad, Mohammad A.
Zhung, Wonho
Stanley, Margaret Elizabeth
Formica, Sydney
Grimaldo-Garcia, Stacey
Obaid, Girgis
Hasan, Tayyaba
Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title_full Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title_fullStr Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title_full_unstemmed Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title_short Photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
title_sort photoimmunotherapy retains its anti-tumor efficacy with increasing stromal content in heterotypic pancreatic cancer spheroids
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443673/
https://www.ncbi.nlm.nih.gov/pubmed/35583476
http://dx.doi.org/10.1021/acs.molpharmaceut.2c00260
work_keys_str_mv AT saadmohammada photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT zhungwonho photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT stanleymargaretelizabeth photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT formicasydney photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT grimaldogarciastacey photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT obaidgirgis photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids
AT hasantayyaba photoimmunotherapyretainsitsantitumorefficacywithincreasingstromalcontentinheterotypicpancreaticcancerspheroids